关于在MASH临床试验中标准化应用组织学分级和分期系统的共识立场声明
Carolin Lackner1, Annette S H Gouw2, Venancio Avancini Ferreira Alves3
1ZLP - Zentrum für Leber- & Pankreaspathologie, ADK Diagnostics, Vienna, Austria; Institute of Pathology, Medical University of Graz, Austria.
Journal of hepatology
|October 10, 2025
概括
对代谢功能障碍相关的脂肪肝炎 (MASH) 的标准化组织学评估对于临床试验至关重要. 国际MASLD病理学小组制定了共识指南,以减少MASH肝活检分级和分期的观察者之间的差异.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病理学 病理学 病理学
- 临床试验 临床试验
背景情况:
- 对代谢功能障碍相关的脂肪肝炎 (MASH) 的组织学评估对于临床试验患者选择和治疗反应评估至关重要.
- 目前的MASH和与代谢功能障碍相关的脂肪性肝病 (MASLD) 的诊断标准和评分系统具有很高的观察者间变异性,影响了试验结果.
- 缺乏标准化的定义和指导方针,阻碍了MASH组织学的准确分类和分期.
研究的目的:
- 建立基于共识的指导方针,用于MASH临床试验中肝活检的组织学评估.
- 改进MASLD中疾病活性分级和纤维化阶段的标准.
- 促进标准化组织病理学解释,并为人工智能驱动的定量组织学评估的发展提供信息.
主要方法:
- 国际MASLD病理学小组 (IMPG) 由25名专家肝病理学家组成,旨在制定这些指南.
- 共识陈述由三个工作小组生成,并通过两轮的德尔菲共识程序来改进.
- 总共有192个最终陈述在参与者之间达到了80%或更高的协议.
主要成果:
- IMPG发表了278份初级声明,其中162份在第一个德尔菲轮获得了80%的协议.
- 经过修订后,33个声明在第二轮重新评估,最终产生了192个最终的共识声明.
- 这些声明提供了关于肝活检处理,MASH诊断,分级和分期的全面指导.
结论:
- IMPG声明提供了第一个标准化指南,用于临床试验中MASH肝活检的组织病理学评估和评分.
- 这些准则旨在加强病理学家之间的共识,减少观察者之间的差异.
- 开发的标准可能有助于创建监督的机器学习算法,用于定量MASLD组织学评估.
更多相关视频
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
2.5K
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.9K
相关概念视频
Group Design
The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between the two are due to...
Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
